Financial reports
NT 10-K
Notice of late annual filing
26 Mar 24
10-Q
2023 Q3
Quarterly report
7 Nov 23
10-Q
2023 Q2
Quarterly report
8 Aug 23
10-Q
2023 Q1
Quarterly report
9 May 23
ARS
2022 FY
Annual report to shareholders
28 Apr 23
10-K
2022 FY
Annual report
29 Mar 23
10-Q
2022 Q3
Quarterly report
7 Nov 22
10-Q
2022 Q2
Quarterly report
4 Aug 22
10-Q
2022 Q1
Quarterly report
9 May 22
10-K
2021 FY
Annual report
4 Mar 22
Current reports
8-K
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
26 Apr 24
8-K
Other Events
16 Apr 24
8-K
Results of Operations and Financial Condition
26 Mar 24
8-K
Entry into a Material Definitive Agreement
18 Mar 24
8-K
Anticipate 85 to 105 patient starts (cell collections) across commercial portfolio in 2024 with first patient start for LYFGENIA expected in Q1 2024
8 Jan 24
8-K
Regulation FD Disclosure
4 Jan 24
8-K
Entry into a Material Definitive Agreement
20 Dec 23
8-K
Entry into a Material Definitive Agreement
18 Dec 23
8-K
Regulation FD Disclosure
14 Dec 23
8-K
Regulation FD Disclosure
11 Dec 23
Registration and prospectus
424B5
Prospectus supplement for primary offering
20 Dec 23
424B5
Prospectus supplement for primary offering
18 Dec 23
424B5
Prospectus supplement for primary offering
8 Aug 23
S-8
Registration of securities for employees
16 Jun 23
S-3
Shelf registration
9 May 23
S-8
Registration of securities for employees
29 Mar 23
424B5
Prospectus supplement for primary offering
19 Jan 23
424B5
Prospectus supplement for primary offering
18 Jan 23
424B5
Prospectus supplement for primary offering
22 Jun 22
S-8
Registration of securities for employees
4 Mar 22
Proxies
DEFA14A
Additional proxy soliciting materials
28 Apr 23
DEF 14A
Definitive proxy
28 Apr 23
PRE 14A
Preliminary proxy
18 Apr 23
DEFA14A
Additional proxy soliciting materials
2 May 22
DEF 14A
Definitive proxy
2 May 22
DEFA14A
Additional proxy soliciting materials
30 Apr 21
DEF 14A
Definitive proxy
30 Apr 21
DEFA14A
Additional proxy soliciting materials
3 Jun 20
DEFA14A
Additional proxy soliciting materials
27 Apr 20
DEF 14A
Definitive proxy
27 Apr 20
Other
EFFECT
Notice of effectiveness
22 May 23
CORRESP
Correspondence with SEC
17 May 23
UPLOAD
Letter from SEC
15 May 23
CT ORDER
Confidential treatment order
12 Dec 22
CT ORDER
Confidential treatment order
22 Jun 21
SEC STAFF
SEC staff action: Order
2 Mar 20
SEC STAFF
SEC staff action: Order
31 Jan 20
CT ORDER
Confidential treatment order
15 Mar 19
CT ORDER
Confidential treatment order
17 May 18
CT ORDER
Confidential treatment order
28 Nov 17
Ownership
SC 13G/A
STATE STREET CORP
10 Apr 24
4
Richard A Colvin
5 Mar 24
4
Joseph Vittiglio
5 Mar 24
4
Andrew Obenshain
5 Mar 24
4
Christopher Krawtschuk
5 Mar 24
4
Thomas J Klima
5 Mar 24
SC 13G/A
PFM Health Sciences, LP
14 Feb 24
SC 13G/A
TANG CAPITAL PARTNERS LP
14 Feb 24
SC 13G
Alyeska Investment Group, L.P.
14 Feb 24
SC 13G
Granahan Investment Management, LLC
14 Feb 24